Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    C16011
Show Display Options
Rank Status Study
1 Recruiting Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: IXAZOMIB;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide

Indicates status has not been verified in more than two years